Bioventix PLC (LON:BVXP - Get Free Report) was down 2.6% during mid-day trading on Friday . The stock traded as low as GBX 3,450 ($43.54) and last traded at GBX 3,456 ($43.62). Approximately 7,664 shares changed hands during trading, an increase of 31% from the average daily volume of 5,833 shares. The stock had previously closed at GBX 3,550 ($44.81).
Bioventix Stock Performance
The firm has a market capitalization of £180.40 million, a price-to-earnings ratio of 2,120.25 and a beta of 0.35. The business has a fifty day moving average price of GBX 3,712.29 and a 200 day moving average price of GBX 4,034.04.
Bioventix Increases Dividend
The company also recently declared a dividend, which was paid on Thursday, November 21st. Shareholders of record on Thursday, November 7th were paid a dividend of GBX 87 ($1.10) per share. The ex-dividend date was Thursday, November 7th. This is a positive change from Bioventix's previous dividend of $68.00. This represents a yield of 2.4%. Bioventix's dividend payout ratio is currently 9,693.25%.
Insider Activity
In other Bioventix news, insider Bruce Hiscock bought 24 shares of Bioventix stock in a transaction that occurred on Friday, November 22nd. The shares were acquired at an average price of GBX 3,822 ($48.24) per share, for a total transaction of £917.28 ($1,157.74). Corporate insiders own 8.02% of the company's stock.
Bioventix Company Profile
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
